{"ok":true,"trend":{"id":606374,"platform":"news","region":"global","key":"novo and hengrui strike $2.6bn obesity drug deal","title":"Novo and Hengrui strike $2.6bn obesity drug deal","url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQZml0TTY3cEhCcldUcnJfZm5MQjg3RUMyS0hMNzRRa0EwdG9nQTIzbUlUZ3FjcnRfenhXaThhaGx0aTgwcThlUUctTC16akhGeTBTUGFHOTVNR0xwQnFIcTdSc1BtZWNsRXE3bTNrc1Q3dkVyazNnNGJQYUxXY2JtT0dCeVR1ZHdjQlJMTm1R?oc=5","first_seen":"2026-10-01T12:06:58.790623Z","last_seen":"2026-10-01T18:57:40.741126Z","last_rank":32,"peak_rank":15,"last_volume":null,"peak_volume":0,"seen_count":4,"score":0.7903125,"category_hint":"labor","section":"business","category":"labor","summary":"Danish drugmaker Novo Nordisk has agreed a deal worth $2.6 billion with China's Hengrui Pharmaceuticals, giving Novo rights to an obesity drug candidate. The agreement underscores fierce competition in the fast-growing weight-loss drug market, where Novo's Wegovy faces mounting rivalry from Eli Lilly and emerging Chinese developers.","why":"Obesity drugs are one of the most competitive and lucrative markets in pharma right now, and a major cross-border deal involving a Chinese partner draws wide attention.","tone":"neutral","entities":["Novo Nordisk","Hengrui Pharmaceuticals","Wegovy"],"summarized_at":"2026-10-01T19:00:25.841835Z","meta":{"via":"scan","lang":"en","term":"strike","source":"bioxconomy.com","published":"Thu, 01 Oct 2026 15:11:15 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Novo Nordisk and Hengrui strike $2.6bn obesity drug deal","section_name":"Business","category_name":"Labor","timeline":[{"captured_at":"2026-10-01T12:06:58.790623Z","rank":31,"volume":null},{"captured_at":"2026-10-01T16:13:19.911003Z","rank":15,"volume":null},{"captured_at":"2026-10-01T17:35:22.041847Z","rank":21,"volume":null},{"captured_at":"2026-10-01T18:57:40.741126Z","rank":32,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQZml0TTY3cEhCcldUcnJfZm5MQjg3RUMyS0hMNzRRa0EwdG9nQTIzbUlUZ3FjcnRfenhXaThhaGx0aTgwcThlUUctTC16akhGeTBTUGFHOTVNR0xwQnFIcTdSc1BtZWNsRXE3bTNrc1Q3dkVyazNnNGJQYUxXY2JtT0dCeVR1ZHdjQlJMTm1R?oc=5","author":"bioxconomy.com","title":"Novo and Hengrui strike $2.6bn obesity drug deal","snippet":null,"posted_at":"2026-10-01T09:18:09Z","likes":null}],"elsewhere":[],"window":"7d"}}